Please login to the form below

Not currently logged in

US biotech Translate Bio appoints Daniella Beckman

She joins the board of directors

Daniella BeckmanTranslate Bio has appointed Daniella Beckman to its board of directors and she will also serve at the US biotech as chairperson of its board’s audit committee.

Beckman has over 15 years’ of financial and operational experience and she currently provides consulting and interim chief financial officer services for early-stage biotech companies, including Tango Therapeutics and Neon Therapeutics.

She said: “I am thrilled to join the Translate Bio board of directors at such a pivotal time for the organisation, I look forward to supporting the company being a part of a dedicated team focused on developing innovative products for genetic diseases.”

Prior to her new role, Beckman was chief financial officer of Idenix Pharmaceuticals - until it was acquired by Merck in 2014 - where she oversaw finance, treasure, capital raises and investor relations.

She has also held various finance positions at Coley Pharmaceuticals - which was acquired by Pfizer in 2008 - and Biogen Idec.

Ronald Renaud, chief executive officer, Translate Bio, said: “Daniella joins our board of directors at an exciting time for Translate Bio. Her financial and operational expertise will be vital as we continue to build the company and bring our first product candidate into the clinic for the treatment of cystic fibrosis in early 2018.”

18th October 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
FCB Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...